HER2-Positive Breast Cancer Market Driven by Therapeutic Advancements

added blog Other

2025-06-02 13:04:01 -

The HER2-Positive Breast Cancer Market encompasses a range of targeted therapeutics designed to inhibit the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in approximately 20–25% of breast cancer cases. Key products include monoclonal antibodies (trastuzumab, pertuzumab), antibody–drug conjugates (ado-trastuzumab emtansine), tyrosine kinase...

0 Comments 0 Shares 292 Views 0 Reviews